source
- Boehringer Ingelheim strikes $7.4 billion deal with Sino Biopharma for preclinical ADC and TCE programsBoehringer Ingelheim announced a major licensing agreement with China's Sino Biopharmaceutical, paying $358 million upfront for a six‑program option covering preclinical antibody‑drug conjugates an…
- Novo reports $2.2 bn impairment hit as pipeline setbacks spur deal huntNovo's third‑quarter earnings disclosed a 15 billion Danish‑krone (about $2.2 bn) impairment charge, largely tied to recent clinical failures. The biggest components were a 4.6 bn‑krone loss from…